+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
ONESOURCE

OneSource Specialty Pharma Share Price

₹1,539.20 -59.7 (-3.73%)
45.62% Gain from 52W Low

12 Aug, 2026 3:57 PM (IST)

OneSource Specialty Pharma live price: ₹1,539.20. It opened at ₹1,599 vs previous close ₹1,599; intraday high/low: ₹1,610/₹1,530. The 50 & 200 DMA stand at ₹1,637.30/₹1,633.90.

OneSource Specialty Pharma Performance

  • Today's Low
  • ₹1,530
  • Today's High
  • ₹1,610
  • 52 Week Low
  • ₹1,057
  • 52 Week High
  • ₹1,925
  • Open Price₹1,599
  • Previous Close₹1,599
  • Volume143,233
  • 50 DMA₹1,637.30
  • 100 DMA₹1,634.30
  • 200 DMA₹1,633.90

OneSource Specialty Pharma Chart

Investment Returns

  • Over 1 Month -5.39%
  • Over 3 Month -14.65%
  • Over 6 Month + 29.17%
  • Over 1 Year -18.74%

Smart Investing Starts Here Start SIP with OneSource Specialty Pharma for Steady Growth!

Invest Now

OneSource Specialty Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -363
  • PEG Ratio
  • 1.3
  • Market Cap Cr
  • 17,651
  • P/B Ratio
  • 3
  • Average True Range
  • 65.5
  • EPS
  • -4.2
  • Dividend Yield
  • 0
  • MACD Signal
  • -27.1
  • RSI
  • 38.86
  • MFI
  • 54.8

Latest Stock News Updates

Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Intimation of Transcript of Earnings call dated July 25, 2026

Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Change in Management

Changes in Senior Management Personnel (SMP) of the Company - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Intimation about publication of newspaper advertisement- Extract of unaudited Standalone and Consolidated financial results for the quarter ended June 30, 2026.

OneSource Specialty Pharma Financials

OneSource Specialty Pharma Technicals

EMA & SMA

Current Price
₹1,539.20
-59.7 (-3.73%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹1,610.60
  • 50 Day
  • ₹1,637.30
  • 100 Day
  • ₹1,634.30
  • 200 Day
  • ₹1,633.90

Resistance and Support

1559.73 Pivot Speed
  • R3 1,669.20
  • R2 1,639.50
  • R1 1,589.40
  • S1 1,509.60
  • S2 1,479.90
  • S3 1,429.80

OneSource Specialty Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-24 Quarterly Results
2026-05-13 Audited Results
2026-01-23 Quarterly Results
2025-11-11 Quarterly Results
2025-08-04 Quarterly Results

OneSource Specialty Pharma Shareholding Pattern

30.48%
26.95%
19.19%
12.98%
10.39%

About OneSource Specialty Pharma

OneSource Specialty Pharma is engaged in the research, development, manufacture and commercialisation of biological drug products in various injectable formats. OneSource also offers end-to-end Contract Development and Manufacturing Operations services across all phases of pre-clinical and clinical development and commercial supply of biologics. View More
  • NSE Symbol
  • ONESOURCE
  • BSE Symbol
  • 544292
  • Executive Director,Managing Director,Chief Executive Officer
  • Neeraj Sharma
  • ISIN
  • INE013P01021

Similar Stocks to OneSource Specialty Pharma

OneSource Specialty Pharma FAQs

OneSource Specialty Pharma share price is ₹1,539 As on 12 August, 2026 | 23:29

The Market Cap of OneSource Specialty Pharma is ₹17650.5 Cr As on 12 August, 2026 | 23:29

The P/E ratio of OneSource Specialty Pharma is -363 As on 12 August, 2026 | 23:29

The PB ratio of OneSource Specialty Pharma is 3 As on 12 August, 2026 | 23:29

The 52 week High & Low of OneSource Specialty Pharma is ₹1925/₹1057 respectively As on 12 August, 2026 | 23:29

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23